Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameCloudr
Stock Code09955
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們為醫院和藥店提供醫療用品和SaaS產品,為製藥公司提供數字營銷服務,為患者提供在線問診和處方開具,所有均圍繞著慢病管理。
Listing Date2022-07-06
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國浙江省杭州市余杭區五常街道文一西路998號(海創園)4樓401、403及405(A)室
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitecloudr.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 30.50 / shares
Offer Price RangeFinal offer price only, no range
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2022-06-23 to 2022-06-28
Global Offering Shares19,000,000 shares
HK Public Offer Shares (Initial)1,900,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)17,100,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO587,038,219 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share61.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 579,500,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 384.9M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +2424%

Valuation & Financials

Market Cap (at Offer Price)HK$ 17,904,665,679
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣4,153.2百萬元
Period-End Cash Balance人民幣11億元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201920202021
Revenue 524,438839,1231,756,731
Cost of sales -462,868-606,367-1,186,707
Gross profit 61,570232,756570,024
Other income and gains, net 4,7655,73229,916
Selling and distribution expenses -149,179-626,020-787,280
Administrative expenses -74,394-316,753-272,327
Operating profit -180,991-836,682-695,911
Net finance costs -57,802-57,802-61,962
Profit before tax -565,376-2,897,855-4,155,507
Income tax expense -139662,314
Profit for the year -565,389-2,896,889-4,153,193
Profit attributable to owners -557,397-2,866,975-4,138,913
Balance Sheet
Item 201920202021
Cash and cash equivalents 601,164914,2261,090,575
Trade and bills receivables 159,159298,545497,266
Inventories 141,96859,405110,924
Total current assets 1,126,1151,532,5472,281,732
Total assets 1,162,1021,687,3422,508,153
Total current liabilities 2,032,2205,067,7489,644,125
Total liabilities 2,033,9245,080,5609,663,284
Total equity -871,822-3,393,218-7,155,131
Equity attributable to owners -854,618-3,361,921-7,137,952
Interest-bearing borrowings 83,900203,511114,383
Cash Flow Statement
Item 201920202021
Net cash from operating activities -360,335-438,465-666,333
Net cash from investing activities 3,405-160,196-155,497
Net cash from financing activities 813,589918,4061,015,371
Net increase in cash 456,659319,745193,541
Depreciation of PP&E 2,9757,07615,409
Amortisation of intangible assets 6,37727,97771,132
Purchase of PP&E -4,246-40,529-88,683
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 28.2
First Day OpenHK$ 30.5
First Day Change-7.54%
First Day Volume4275800.0
First Day Turnover119515000.0
Use of Proceeds
1、約60%預計將用于業務擴張,在全國范圍內擴大我們的醫院網絡; 2、約25%預計將用于提高我們的醫學知識和技術能力,以加強我們在數字醫療行業的領導地位; 3、約5%預計將用于通過戰略伙伴關系、投資和收購其他業務來擴大我們的生態系統,以補充我們的有機成長戰略; 4、約10%預計將用于營運資金和一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (4)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 招银国际融资有限公司 CE AVM940
Joint Bookrunners (5)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 招银国际融资有限公司 CE AVM940 VALUABLE CAPITAL LIMITED CE AUL711
Joint Lead Managers (5)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 招银国际融资有限公司 CE AVM940 VALUABLE CAPITAL LIMITED CE AUL711

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 156,998,750 HKD — 27.09% — 6 months 2023-01-06
2 Sanofi Foreign Participations B.V 117,748,300 HKD — 20.32% — 6 months 2023-01-06
3 Tasly International Capital Limited 39,247,400 HKD — 6.77% — 6 months 2023-01-06
4 扬子江(香港)有限公司 39,247,400 HKD — 6.77% — 6 months 2023-01-06

Directors & Management

PositionChinese nameEnglish Name
Chairman匡明—
Company Secretary劉夢雅—
No director data available.

Major Shareholders

Major Shareholders & Holdings匡明先生(透過HaoYuan health Limited及表決權協議)控制約21.88%表決權;HaoYuan health Limited持股15.23%;Prime Forest Assets Limited持股12.49%
About this page

This page shows Cloudr (09955) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect